Literature DB >> 29242962

[Mucous membrane pemphigoid].

M M Holtsche1, D Zillikens2, E Schmidt2.   

Abstract

Mucous membrane pemphigoid (MMP) is a pemphigoid disease defined by the presence of autoantibodies against the dermal-epidermal junction and predominant involvement of mucous membranes. Diagnosis is made by the clinical presentation and linear deposits of IgG and/or IgA and/or C3 at the dermal-epidermal junction by direct immunofluorescence microscopy of a perilesional biopsy. Circulating autoantibodies can be detected in most patients by indirect immunofluorescence microscopy on salt-split human skin as well as ELISA and immunoblotting with recombinant and cell-derived target antigens. For systemic treatment of MMP, corticosteroids, dapsone, mycophenolates, and azathioprine are applied. In severe cases and in cases with rapid disease progression cyclophosphamide, rituximab, high-dose intravenous immunoglobulins, and immunoadsorption are used. For the successful management of MMP patients, close cooperation with dentists, ophthalmologists, ENT specialists, gynecologists, and gastroenterologists is essential.

Entities:  

Keywords:  Autoantibodies; Basal membrane zone; Immunofluorescence; Immunosuppression; Mucous membrane erosions

Mesh:

Substances:

Year:  2018        PMID: 29242962     DOI: 10.1007/s00105-017-4089-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  74 in total

1.  No association between cicatricial pemphigoid and malignant disease.

Authors:  M Nayar; F Wojnarowska
Journal:  Br J Dermatol       Date:  1991-08       Impact factor: 9.302

Review 2.  Immunoadsorption in dermatology.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Arch Dermatol Res       Date:  2010-01-05       Impact factor: 3.017

Review 3.  Pemphigoid diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Lancet       Date:  2012-12-11       Impact factor: 79.321

4.  Impact of clinical factors on the long-term functional and anatomic outcomes of osteo-odonto-keratoprosthesis and tibial bone keratoprosthesis.

Authors:  María Fideliz De La Paz; Juan Álvarez De Toledo; Victor Charoenrook; Saadettin Sel; José Temprano; Rafael I Barraquer; Ralph Michael
Journal:  Am J Ophthalmol       Date:  2011-02-18       Impact factor: 5.258

Review 5.  Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts.

Authors:  Dedee F Murrell; Branka Marinovic; Frederic Caux; Catherine Prost; Razzaque Ahmed; Katarzyna Wozniak; Masayuki Amagai; Johann Bauer; Stefan Beissert; Luca Borradori; Donna Culton; Janet A Fairley; David Fivenson; Marcel F Jonkman; M Peter Marinkovich; David Woodley; John Zone; Valeria Aoki; Philippe Bernard; Leena Bruckner-Tuderman; Giuseppe Cianchini; Vanessa Venning; Luis Diaz; Rudiger Eming; Sergei A Grando; Russell P Hall; Takashi Hashimoto; Josep E Herrero-González; Michael Hertl; Pascal Joly; Sarolta Karpati; Jaehwan Kim; Soo Chan Kim; Neil J Korman; Cezary Kowalewski; Sang Eun Lee; David R Rubenstein; Eli Sprecher; Kim Yancey; Giovanna Zambruno; Detlef Zillikens; Serge Doan; Benjamin S Daniel; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2014-11-04       Impact factor: 11.527

6.  Immunosuppressive therapy for progressive ocular cicatricial pemphigoid.

Authors:  C S Foster; L A Wilson; M B Ekins
Journal:  Ophthalmology       Date:  1982-04       Impact factor: 12.079

7.  A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

Authors:  Erik Letko; Elisabetta Miserocchi; Yassine J Daoud; William Christen; C Stephen Foster; A Razzaque Ahmed
Journal:  Clin Immunol       Date:  2004-06       Impact factor: 3.969

8.  Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to the beta4 integrin subunit.

Authors:  E Letko; H M Gürcan; G N Papaliodis; W Christen; C S Foster; A R Ahmed
Journal:  Clin Exp Dermatol       Date:  2007-05-25       Impact factor: 3.470

9.  Association of autoimmunity and cicatricial pemphigoid: is there an immunogenetic basis?

Authors:  M Nayar; F Wojnarowska; V Venning; C J Taylor
Journal:  J Am Acad Dermatol       Date:  1991-12       Impact factor: 11.527

10.  Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy.

Authors:  Nina van Beek; Kristin Rentzsch; Christian Probst; Lars Komorowski; Michael Kasperkiewicz; Kai Fechner; Inga M Bloecker; Detlef Zillikens; Winfried Stöcker; Enno Schmidt
Journal:  Orphanet J Rare Dis       Date:  2012-08-09       Impact factor: 4.123

View more
  5 in total

Review 1.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

2.  [85-year-old male with cutaneous blisters : Preparation for the medical specialist examination: Part 25].

Authors:  Mareike Witte; Enno Schmidt; Ralf Ludwig
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 3.  [Paraneoplastic autoimmune dermatoses].

Authors:  D Didona; M Hertl
Journal:  Hautarzt       Date:  2021-03-01       Impact factor: 0.751

Review 4.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

Review 5.  Diagnosis of Autoimmune Blistering Diseases.

Authors:  Mareike Witte; Detlef Zillikens; Enno Schmidt
Journal:  Front Med (Lausanne)       Date:  2018-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.